Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPENOVA: Azenosertib vs Chemotherapy in Platinum-Resistant Ovarian Cancer
NCT07546500Phase 3Recruiting
- Sponsor
- Zentalis Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of azenosertib in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Zentalis Pharmaceuticals. Started Apr 2026; status: recruiting.
02
Drugs
azenosertib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT07546500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07546500.